Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis shows Galvus to have ‘reinforced’ efficacy profile

Novartis shows Galvus to have ‘reinforced’ efficacy profile

7th November 2007

Novartis has reported new clinical data that further confirms the efficacy of its oral medicine Galvus in type 2 diabetes treatment.

The data, to be published in the journal Diabetes, Obesity and Metabolism, demonstrates that a twice-daily dose of Galvus 50mg is as effective as a thiazolidinedione (TZD), as well as being tolerated and not causing weight gain.

A daily dose of Galvus in addition to metformin treatment reduced blood sugar levels as effectively as adding a 30mg once-daily dose of pioglitazone, a member of the TZD class of diabetes medicines.

In addition, Galvus was shown to be weight neutral while the addition of the TZD was associated with weight gain of up to 1.9 kg after 24 weeks of treatment.

Over 500 patients with type 2 diabetes were enrolled in the 24-week study, all of whom had inadequately controlled diabetes despite taking the oral medicine metformin.

Also this week, Novartis has provided a safety update to European regulators which shows numerically less frequent liver enzyme elevations in patients taking Galvus 50mg twice-daily instead of 100mg once-daily.

Novartis offers a wide range of healthcare products through its vaccines and diagnostics, pharmaceuticals and consumer health divisions.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.